US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Biogen Inc.

BIIBNASDAQ

202.54

USD
+3.14
(+1.57%)
After Hours Market
20.50P/E
13Forward P/E
0.79P/E to S&P500
29.662BMarket CAP
- -Div Yield

Biogen Inc.

NASDAQ:BIIB

RECENT
PRICE

202.54

P/E
RATIO

20.50

(PEG:-0.34)

P/E RATIO
RELATIVE
TO S&P

0.79

DIV
YLD

NaN%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

- - Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 05/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

5.53

0.64

1.90

- -

10.04

2.02

2.33

- -

14.02

2.68

4.41

- -

15.23

3.38

3.16

- -

18.69

3.98

5.75

- -

20.83

5.09

6.09

- -

23.18

5.80

6.80

- -

29.26

7.86

(4.91)

- -

41.05

12.42

11.23

- -

46.66

15.37

13.32

- -

52.42

16.95

17.38

- -

57.73

11.94

12.17

- -

65.66

21.62

25.87

- -

76.85

31.47

34.25

- -

83.56

24.86

22.86

- -

68.25

9.67

20.79

- -

- -

- -

- -

- -

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.59

21.12

0.90

17.52

0.94

19.86

0.58

21.65

0.69

21.39

1.04

26.51

1.10

29.26

14.81

36.38

1.22

45.73

2.79

40.63

3.33

55.59

9.23

59.33

4.32

63.64

3.58

71.32

3.43

66.50

1.83

67.72

- -

- -

CAPEX per share

Book Value per share

339

316

292

287

252

242

238

237

236

231

218

213

205

187

161

161

- -

Comm.Shares outs.(m)

71.8

4.0

- -

28.3

1.6

- -

20.7

1.0

- -

14.4

0.2

- -

14.1

0.7

- -

18.2

1.1

- -

23.5

1.6

- -

27.6

1.6

- -

25.5

1.4

- -

22.8

1.1

- -

16.6

0.7

- -

24.5

1.0

- -

14.5

0.6

- -

8.4

0.3

- -

11.7

0.3

- -

30.1

1.0

- -

20.5

0.8

- -

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (31/3/22 | Q1)

Total liabilities
$12,394 m.

Total assets
$23,614 m.

Long-term debt
$6,588 m.

Cash and equiv.
$1,749 m.

Goodwill $5,758 m.

Retained earnings $14,216 m.

Common stock - - m. shares

Market Capitalisation
$29,336 m. (as of 24/5/22)

5,049

34.2%

5,516

33.6%

6,932

36.3%

9,703

40.9%

10,764

45.4%

11,449

45.0%

12,274

43.5%

13,453

43.8%

14,378

49.0%

13,445

33.8%

10,982

25.9%

- -

- -

Revenue (m)

Operating margin

359

1,234

366

1,380

532

1,862

688

2,935

600

3,547

683

3,703

1,081

2,539

1,017

4,431

681

5,889

457

4,001

488

1,556

- -

- -

Depreciation (m)

Net profit (m)

26.0%

24.5%

25.4%

25.0%

24.2%

26.9%

25.1%

30.2%

24.4%

33.0%

25.1%

32.3%

47.9%

20.7%

24.2%

32.9%

16.3%

41.0%

19.7%

29.8%

3.0%

14.2%

- -

- -

Income tax rate

Net profit margin

2,063

1,061

6,425

1,587

687

6,962

1,427

592

8,620

2,453

582

10,809

4,123

6,522

9,373

5,312

6,513

12,140

4,505

5,935

12,613

4,346

5,937

13,040

3,518

4,459

13,343

3,145

7,828

10,700

3,558

6,604

10,896

3,969

6,588

11,242

Working capital (m)

Long-term debt (m)

Equity (m)

15.6%

18.9%

19.2%

16.6%

18.6%

19.8%

18.7%

21.0%

21.6%

24.5%

27.6%

27.2%

21.5%

24.6%

37.8%

20.0%

22.7%

30.5%

13.5%

22.2%

20.1%

20.9%

23.9%

34.0%

27.1%

26.6%

44.1%

20.1%

21.2%

37.4%

9.3%

7.8%

14.3%

- -

- -

- -

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

4,476

2,893

3,824

Receivables

2,471

2,327

1,962

Inventory

804

1,069

1,352

Other

631

881

741

Current assets

8,382

6,887

7,857

Acc. Payable

531

455

589

Debt due

1,496

- -

999

Other

2,837

3,287

2,710

Current liab.

4,864

3,742

4,298

100.0%

12.4%

100.0%

60.8%

100.0%

(34.4)%

100.0%

33.4%

100.0%

162.7%

100.0%

26.4%

100.0%

52.8%

100.0%

82.1%

100.0%

91.6%

100.0%

181.6%

100.0%

53.8%

100.0%

- -

Plowback ratio

Div.&Repurch. to FCF

Biogen Inc. (US) started trading on September 2, 1991 (cik: 0000875045), operates in the Healthcare sector (Drug Manufacturers—General industry), has 9,610 full-time employees, and is led by Mr. Michel Vounatsos. Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

-2.08%

9.09%

Cash flow

18.52%

-46.49%

Earnings

3.56%

11.18%

Dividends

- -

- -

Book value

-3.07%

6.34%

Insider trading

Type

Shares

Date

Murphy Nicole

Exempt

239

04/01/22

Murphy Nicole

InKind

84

04/01/22

Murphy Nicole

Exempt

239

04/01/22

Vounatsos Michel

Other

8,909

02/18/22

Vounatsos Michel

Exempt

6,191

02/18/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

- -

- -

- -

- -

- -

2021

- -

- -

- -

- -

- -

2022

- -

- -

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

- -

- -

- -

- -

- -

2021

- -

- -

- -

- -

- -

2022

- -

- -

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2019

- -

- -

- -

- -

- -

2020

- -

- -

- -

- -

- -

2021

- -

- -

- -

- -

- -

05/03/2022

Alzheimer’s Patients Now Less Likely to Receive Biogen’s Aduhelm Treatment

The Wall Street Journal - Read more...

05/03/2022

Biogen CEO to Resign After Alzheimer’s Drug Struggles

The Wall Street Journal - Read more...

04/07/2022

Medicare Limits Payments for Biogen’s Alzheimer’s Drug

The Wall Street Journal - Read more...

03/14/2022

Biogen and Eisai Rewrite Alzheimer’s Drug Marketing Pact

The Wall Street Journal - Read more...

02/23/2022

Medicare Proposal on Alzheimer’s Drug Draws Criticism From Drugmakers

The Wall Street Journal - Read more...

01/28/2022

Biogen to Sell Biosimilar-Venture Stake to Partner Samsung Biologics

The Wall Street Journal - Read more...

01/12/2022

Biogen, PayPal, Block, Ally Financial: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...

01/12/2022

Medicare to Pay for Biogen’s New Alzheimer’s Drug in Clinical-Trial Patients

The Wall Street Journal - Read more...

01/04/2022

How Biogen Fumbled Aduhelm, Its Once-Promising Alzheimer’s Drug

The Wall Street Journal - Read more...

12/20/2021

Biogen Cuts Price for Alzheimer’s Drug Aduhelm by Half

The Wall Street Journal - Read more...

11/09/2021

Biogen Investigates Death of Aduhelm Patient

The Wall Street Journal - Read more...

10/20/2021

Biogen’s New Alzheimer’s Drug Meets Slow Rollout

The Wall Street Journal - Read more...

09/21/2021

Apple iPhone Features Would Detect Depression, Cognitive Decline

The Wall Street Journal - Read more...

09/13/2021

Airbnb, Apache, Biogen: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

08/27/2021

Biogen’s New Alzheimer’s Drug Beyond Reach for Many Patients

The Wall Street Journal - Read more...

08/12/2021

VA Health System Won’t Cover Biogen’s Alzheimer’s Drug

The Wall Street Journal - Read more...

07/22/2021

Biogen Sees Heavy Patient Interest in New Alzheimer’s Drug

The Wall Street Journal - Read more...

07/09/2021

FDA Seeks Probe of Talks Between Staff, Biogen on Alzheimer’s Drug

The Wall Street Journal - Read more...

07/09/2021

Biogen Alzheimer’s Drug Will Exceed the $56,000 List Price for Many, Analysis Says

The Wall Street Journal - Read more...

07/08/2021

FDA Narrows Suggested Uses for New Alzheimer’s Drug

The Wall Street Journal - Read more...

06/28/2021

Costly New Alzheimer’s Drug Could Force Medicare to Restrict Access

The Wall Street Journal - Read more...

06/11/2021

FDA’s Approval of Alzheimer’s Drug Leads to Third Adviser’s Resignation

The Wall Street Journal - Read more...

06/10/2021

GameStop, Clover Health, FuelCell Energy: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

06/07/2021

First Alzheimer’s Drug to Slow Disease Is Approved by FDA

The Wall Street Journal - Read more...

01/29/2021

FDA Extends Review of Biogen, Eisai’s Alzheimer’s Drug

The Wall Street Journal - Read more...

07/22/2020

Biogen Taps Iqvia CFO as New Finance Chief

The Wall Street Journal - Read more...